华领医药聘请阿斯利康中国糖尿病领域资深人士担任营销战略和市场部副总裁

中国上海 - 2018年8月9日

中国创新型医药领军企业 -- 华领医药今日宣布，在中国地区有丰富销售和市场营销经验的徐文洁女士正式加入华领医药，担任副总裁，主管营销战略和市场部。徐文洁女士拥有20多年市场营销以及战略部署的成功经验，曾在多个跨国制药公司担任重要职位。加入华领医药之前，担任阿斯利康中国心血管、肾脏及代谢业务市场部执行总监，主要负责糖尿病药品在中国的市场销售和战略部署，包括领导团队成功上市安达唐。2007年2月至2015年12月期间， 徐女士在礼来中国负责销售和市场营销业务，并且从2009年开始专注于糖尿病领域。在此之前，徐女士曾在包括安进中国在内的多家国内外药企负责市场和销售工作。徐女士在中国药科大学获得药物分析学士学位，美国Emory大学获得工商管理硕士学位。

▲徐文洁女士

 

作为华领负责医药的营销战略和市场的副总裁，徐女士的主要职责将包括制定公司产品的商业化与市场营销策略，管理市场营销和产品推广活动，以及销售人员的培训。

华领医药在2016年成功完成了其2型糖尿病首创新药“葡萄糖激酶正向别构调节剂(PAM)-Dorzagliatin(HMS5552)”的II期验证性临床研究，该研究在全国22家具有领先水平的临床中心开展，入组病人数是258位。II期临床试验的数据已于2018年5月4日，在《柳叶刀》子刊《The Lancet Diabetes & Endocrinology》上发表。目前，华领医药已在国内启动NDA申报阶段的工作，2个III期临床研究正同时展开，其中包括由中华医学会糖尿病学分会候任主委朱大龙教授领衔的，针对2型糖尿病新发患者的Dorzagliatin单药研究，以及由中华医学会糖尿病学分会前任主委杨文英教授领衔的Dorzagliatin和二甲双胍联合用药研究,全国共有110家临床中心参与了本次研究。

“我们很高兴有徐女士加入华领团队，领导我们的商业化和市场营销工作。”华领医药首席执行官陈力博士说。“徐女士在中国糖尿病药市场的销售和营销方面经验丰富。作为华领医药的营销战略和市场部负责人，她在中国糖尿病市场的丰富经验将对我们向全世界最大的糖尿病人群推广 Dorzagliatin 起到至关重要的作用。”

关于华领

华领医药是一家立足中国的创新型药物研发领军企业，目前专注于全球首创、用于治疗2型糖尿病的口服药物Dorzagliatin (HMS5552)的开发。Dorzagliatin 是第四代葡萄糖激酶激活剂，由Roche研发，并以临床前阶段化合物授权给华领医药，华领拥有其全球开发权。公司由创新药研发经验丰富的创始人兼首席执行官陈力博士（罗氏中国前首席科学官）和生物医药领域企业家以及知名投资机构共同创立。公司核心管理团队由在全球药物研发领域拥有丰富经验的高端人才组成，并拥有由业内重要意见领袖、专家和科学家组成的投资顾问委员会。 据Frost＆Sullivan称，2017年全球有4.35亿人患有2型糖尿病，而中国拥有世界上最大的糖尿病人群，2017年有1.2亿人，到目前尚未确诊的占52.8%。

Hua Medicine hires AstraZeneca China Diabetes Veteran as VP, Head of Commercial Strategy and Marketing 

Shanghai, China – August 9, 2018

Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced Wenjie Xu, an experienced sales & marketing veteran in China, joins Hua Medicine as VP, Head of Commercial Strategy and Marketing.

Ms. Wenjie Xu brings with her over 20 years of experience working in various sales and marketing roles at multi-national pharmaceutical firms in China. Prior to joining Hua, she was the Executive Director of the Cardiovascular, Renal, and Metabolic Business Unit at AstraZeneca China. Ms. Xu’s principal responsibility at AstraZeneca China was sales and marketing of their diabetes franchise in China, including the launch of Forxiga (dapagliflozin) She also served in various sales and marketing roles at Eli Lilly from February 2007 to December 2015, focused on diabetes starting in 2009. Prior to Eli Lilly, Ms. Xu served in sales and marketing functions of various international and domestic pharmaceutical companies, including Amgen China. Ms. Xu received a Bachelor’s degree in Pharmaceutical analysis from the China Pharmaceutical University, and a Master of Business Administration from Goizueta Business School, Emory University.

As Hua’s Head of Commercial Strategy & Marketing, Wenjie’s key responsibilities will be to develop the commercial and marketing strategies of the company’s products, manage marketing and product education activities, and the training of sales staff.

Hua Medicine successfully completed its proof-of-concept study Phase II clinical trial for Dorzagliatin (HMS5552), a novel 1st-in-class Glucokinase Positive Allosteric Modulator (PAM) for the treatment of diabetes in 258 patients in 22 leading hospital centers across China in 2016. The Phase II data was published in the Lancet, Diabetes and Endocrinology on May 8, 2018. In China, the company has initiated the NDA enabling process and has started two Phase III clinical trials targeting drug-naive and metformin treated T2D patients in China led by Professor Dalong Zhu, President-elect of China Diabetes Society (CDS), and Professor Wenying Yang, Former President of CDS, with 110 clinical sites located throughout China participating.

"We are very excited to have Wenjie join the Hua team, leading our commercialization and marketing efforts.” said Dr. Li Chen, CEO of Hua Medicine. "Wenjie is highly experienced in the sales and marketing of diabetes drugs in the China market. As Hua’s head of commercial strategy and marketing, her experience and network in China’s diabetes market will be critical in helping us deliver Dorzagliatin to the world’s largest diabetes population."

Hua Medicine is a China-based drug development company currently focused on developing a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 Diabetes (T2D). Dorzagliatin is a fourth generation glucokinase activator, originated at Roche AG, and in-licensed by Hua Medicine as a pre-clinical stage compound.  Hua Medicine retains global rights to Dorzagliatin.  Founded and funded by well-known and highly experienced US and China biotech specialists, including our founder and CEO, Dr. Li Chen (the former Chief Scientific Officer of Roche China).Hua Medicine is comprised of a team with extensive experience in global pharmaceutical research and development, and a portfolio advisory board comprised of some of the industry’s most significant key opinion leaders, academics, and scientists.  According to Frost & Sullivan, there were 435 million individuals with T2D in 2017 globally. China has the world’s largest diabetes population, with 120 million individuals in 2017, and 52.8% are currently undiagnosed.

华领医药/报道

本文由华领医药团队整理，欢迎分享。转载请于文章开头注明 “本文来源于华领医药微信公众号（ID：huamedicine )”